SCHEMBL20119772

SCHEMBL20119772

CCOc1nc2c(NCc3nccs3)nc(Cl)nc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.37
TRPM5 Q9NZQ8 1/20 0.36
KHK P50053 2/20 0.33
KDM1A O60341 1/20 0.32
MAOB P27338 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TLR7 Q9NYK1 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31
CCNE2 O96020 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
CDK1 P06493 1/20 0.31
IGF1R P08069 1/20 0.31
PTGS2 P35354 1/20 0.30
CLK1 P49759 1/20 0.30
CLK2 P49760 1/20 0.30
CLK3 P49761 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119469 0.92 HRH4 (0.35) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119759 0.91 HRH4 (0.35) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119527 0.91 HRH4 (0.37) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119715 0.91 TRPM5 (0.36) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119818 0.89 HRH4 (0.35) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119786 0.89 HRH4 (0.35) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119828 0.88 TRPM5 (0.34) HRH4TRPM5KDM1AMAOBSMN1; SMN2
SCHEMBL20119868 0.88 HRH4 (0.35) HRH4TRPM5KHKKDM1AMAOB
SCHEMBL20119805 0.87 HRH4 (0.34) HRH4TRPM5KHKCCNE2CCNE1
SCHEMBL20119940 0.87 HRH4 (0.34) HRH4TRPM5KHK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885KHK 2342/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885KHK 2342/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885KHK 2342/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885KHK 2342/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885KHK 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.